• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genmab A/S ADR (NQ: GMAB )

    25.48 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 25.48
    Bid (Size) 25.63 (18)
    Ask (Size) 25.67 (12)
    Prev. Close 25.48
    Today's Range 25.48 - 25.48
    52wk Range 24.53 - 42.72
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NASDAQ:GMAB, an undervalued stock with good fundamentals.
    GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
    Via Chartmill
    Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire

    Performance

    YTD
    -20.65%
    -20.65%
    1 Month
    -8.74%
    -8.74%
    3 Month
    -14.67%
    -14.67%
    6 Month
    -22.25%
    -22.25%
    1 Year
    -32.70%
    -32.70%

    More News

    Read More
    AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
    Via Benzinga
    Exposures Product Safety
    EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    From Genmab A/S
    Via Business Wire
    10 Analysts Assess Genmab: What You Need To Know
    Via Benzinga
    What 9 Analyst Ratings Have To Say About Genmab
    Via Benzinga
    7 Biotech Stocks to Buy on the Dip: June 2024
    Via InvestorPlace
    Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
    Via Chartmill
    7 Stocks That Could Safely 10X by 2030
    Via InvestorPlace
    Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    From Genmab A/S
    Via Business Wire
    NASDAQ:GMAB is showing good growth, while it is not too expensive.
    Via Chartmill
    Decoding 9 Analyst Evaluations For Genmab
    Via Benzinga
    Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
    From Genmab A/S
    Via Business Wire
    NASDAQ:GMAB is not too expensive for the growth it is showing.
    Via Chartmill
    Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
    From Genmab A/S
    Via Business Wire
    Genmab Completes Acquisition of ProfoundBio
    From Genmab A/S
    Via Business Wire
    7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
    Via InvestorPlace
    Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
    From Genmab A/S
    Via Business Wire
    GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
    From Genmab A/S
    Via Business Wire
    FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
    From Pfizer Inc.
    Via Business Wire
    Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
    Via Investor's Business Daily
    ProfoundBio Discovers The Joys Of Having A Wealthy Owner
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.